ライフサイエンスコーパス: cardiovascular morbidity

1 the several risk factors for CKD and related cardiovascular morbidity.

2 aired glucose tolerance, hyperlipidemia, and cardiovascular morbidity.

3 e relationship between caregiving stress and cardiovascular morbidity.

4 raction of heart and brain in stress-induced cardiovascular morbidity.

5 Low energy expenditure is a risk for cardiovascular morbidity.

6 ator-1 (PAI-1) are associated with long-term cardiovascular morbidity.

7 nts into three risk groups for mortality and cardiovascular morbidity.

8 tion that has been shown to be predictive of cardiovascular morbidity.

9 nts have also been associated with increased cardiovascular morbidity.

10 igh-sensitivity CRP are predictive of future cardiovascular morbidity.

11 lucidate the link between RBC dyscrasias and cardiovascular morbidity.

12 en found to have a protective effect against cardiovascular morbidity.

13 n, diabetes mellitus, and a greater risk for cardiovascular morbidity.

14 ated a reduction in both cerebrovascular and cardiovascular morbidity.

15 and are associated with clinically important cardiovascular morbidity.

16 ence, which can be associated with increased cardiovascular morbidity.

17 hese antibodies correlate with mortality and cardiovascular morbidity.

18 hypoxia (CIH), and causally associates with cardiovascular morbidities.

19 tality similar to expected (P=0.20) but high cardiovascular morbidity (6.2%/y, P<0.01) and notable MV

20 despite its associations with higher risk of cardiovascular morbidity, accelerated cognitive decline

21 racteristics offers hope of reducing serious cardiovascular morbidity after HCT.

22 itors such as captopril reduce mortality and cardiovascular morbidity among patients with myocardial

23 cination against seasonal influenza prevents cardiovascular morbidity and all-cause mortality in pati

24 s populations as an independent predictor of cardiovascular morbidity and all-cause mortality.

25 s of this low-expression variant of FABP4 on cardiovascular morbidity and carotid atherosclerosis on

26 In addition to preventing cardiovascular morbidity and death, further study is war

27 s more effective than atenolol in preventing cardiovascular morbidity and death, predominantly stroke

28 disease, who exhibit unusually high rates of cardiovascular morbidity and death, tend to be hyperhomo

29 ry hypertension (PH) is a key contributor to cardiovascular morbidity and early mortality; however, r

30 ey transplantation, complications, including cardiovascular morbidity and graft loss, contribute to r

31 Insulin resistance (IR) increases cardiovascular morbidity and is associated with mitochon

32 itors, or statins, have been shown to reduce cardiovascular morbidity and mortality among a wide spec

33 ble therapies, there is a marked increase in cardiovascular morbidity and mortality among patients su

34 argets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons wit

35 intervention for weight loss would decrease cardiovascular morbidity and mortality among such patien

36 was associated with remarkable reduction of cardiovascular morbidity and mortality and all-cause dea

37 ociated with respiratory diseases as well as cardiovascular morbidity and mortality and can reduce lu

38 ion have been reported to be associated with cardiovascular morbidity and mortality and increased car

39 Air pollution exposure increases cardiovascular morbidity and mortality and is a major gl

40 rain is associated with an increased risk of cardiovascular morbidity and mortality and of all-cause

41 th most antihypertensive medications reduces cardiovascular morbidity and mortality and possibly cogn

42 rysms in HCM are associated with substantial cardiovascular morbidity and mortality and raise novel t

43 high risk for metabolic syndrome and related cardiovascular morbidity and mortality and require regul

44 Cardiovascular morbidity and mortality and shortened all

45 that this hyperactivity may explain delayed cardiovascular morbidity and mortality and that it arise

46 Obesity is associated with increased cardiovascular morbidity and mortality and with elevated

47 Cardiovascular morbidity and mortality are higher among

48 Data from observational studies suggest that cardiovascular morbidity and mortality are increased in

49 Cardiovascular morbidity and mortality are reduced by tr

50 Atherothrombosis is the leading cause of cardiovascular morbidity and mortality around the globe.

51 Cardiovascular morbidity and mortality as a result of in

52 nditions may be at increased risk of adverse cardiovascular morbidity and mortality associated with a

53 ith a high-sensitivity assay (hs-GH) predict cardiovascular morbidity and mortality at the population

54 ysfunction that is associated with increased cardiovascular morbidity and mortality caused by obesity

55 systolic blood pressure of 120 mm Hg reduces cardiovascular morbidity and mortality compared with a h

56 ibitor sacubitril/valsartan (LCZ696) reduced cardiovascular morbidity and mortality compared with ena

57 Heart failure-induced cardiovascular morbidity and mortality constitute a majo

58 t blood pressure to occurrence of subsequent cardiovascular morbidity and mortality depending on the

59 x is independently associated with increased cardiovascular morbidity and mortality during progressio

60 nd-stage renal disease and limit or abrogate cardiovascular morbidity and mortality has led to increa

61 type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been dete

62 Cardiovascular morbidity and mortality have been found t

63 y with the smaller doses now being used; (2) cardiovascular morbidity and mortality have been reduced

64 he past three decades, age-adjusted rates of cardiovascular morbidity and mortality have fallen in th

65 sity are predisposed to an increased risk of cardiovascular morbidity and mortality in adulthood.

66 ry behavior is associated with all-cause and cardiovascular morbidity and mortality in adults such th

67 index and increased glucose tolerance); and cardiovascular morbidity and mortality in adults without

68 or the combination had comparable effects on cardiovascular morbidity and mortality in African Americ

69 considered recently as potent predictors of cardiovascular morbidity and mortality in all explored p

70 and soft tissue calcification contributes to cardiovascular morbidity and mortality in both the gener

71 tem remain prevalent and important causes of cardiovascular morbidity and mortality in developing cou

72 ysteinemia is an independent risk factor for cardiovascular morbidity and mortality in end-stage rena

73 ctors fail to explain the increased risk for cardiovascular morbidity and mortality in ESRD.

74 heart disease and with an increased risk of cardiovascular morbidity and mortality in hypertensive p

75 failure of antioxidant therapy in preventing cardiovascular morbidity and mortality in major clinical

76 Statins reduce cardiovascular morbidity and mortality in many patients

77 cence genes have been associated with higher cardiovascular morbidity and mortality in nontransplant

78 appear to be an independent risk factor for cardiovascular morbidity and mortality in older women.

79 Low Hgb levels correlate with increased cardiovascular morbidity and mortality in patients prese

80 m-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with

81 onstrated that medical therapy can attenuate cardiovascular morbidity and mortality in patients with

82 rials have shown that statin therapy reduces cardiovascular morbidity and mortality in patients with

83 Heart failure is a major contributor to cardiovascular morbidity and mortality in patients with

84 ors have a relatively lesser contribution to cardiovascular morbidity and mortality in patients with

85 nvestigated the effects of statin therapy on cardiovascular morbidity and mortality in patients with

86 e medical therapy is feasible and relates to cardiovascular morbidity and mortality in patients with

87 nsporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with

88 ary artery disease (CAD) is a major cause of cardiovascular morbidity and mortality in patients with

89 Statins significantly reduce cardiovascular morbidity and mortality in patients with

90 t estrogen replacement therapy (ERT) reduces cardiovascular morbidity and mortality in postmenopausal

91 to develop effective interventions to reduce cardiovascular morbidity and mortality in RA patients.

92 Dyslipidemia is a risk factor for premature cardiovascular morbidity and mortality in renal transpla

93 y underlie cardiac dysfunction and increased cardiovascular morbidity and mortality in subjects with

94 ischemia and may contribute to the increased cardiovascular morbidity and mortality in such patients.

95 an independent and incremental predictor of cardiovascular morbidity and mortality in T2DM patients

96 the prognostic utility of GLS for long-term cardiovascular morbidity and mortality in the general po

97 rate has been shown to be a risk factor for cardiovascular morbidity and mortality in the general po

98 iographic monitoring is required to minimize cardiovascular morbidity and mortality in this specific

99 en the exposure to air pollution and overall cardiovascular morbidity and mortality is increasingly f

100 association of particulate matter (PM) with cardiovascular morbidity and mortality is well documente

101 hat individuals with schizophrenia have high cardiovascular morbidity and mortality is well establish

102 tatic factors that are in turn implicated in cardiovascular morbidity and mortality later in life.

103 Whether this translates to lower cardiovascular morbidity and mortality long term is uncl

104 ay be a potential precursor of the increased cardiovascular morbidity and mortality observed in patie

105 and this has been associated with the excess cardiovascular morbidity and mortality observed in this

106 antiplatelet medications, is known to reduce cardiovascular morbidity and mortality rates in these pa

107 gested that antioxidant therapy may decrease cardiovascular morbidity and mortality rates, although t

108 Cardiovascular morbidity and mortality resulting from co

109 yle Changes Diet are effective in decreasing cardiovascular morbidity and mortality risk, and such di

110 Peripheral arterial disease is a marker of cardiovascular morbidity and mortality risk.

111 ollutants over years confers higher risks of cardiovascular morbidity and mortality than shorter-term

112 et and physical activity have lower rates of cardiovascular morbidity and mortality than those who do

113 0-75 years examined in 1989 and followed for cardiovascular morbidity and mortality through 2000 to a

114 tracardiac myxomas are significant causes of cardiovascular morbidity and mortality through embolic s

115 B]) and QRS morphology in those with BBB, on cardiovascular morbidity and mortality was assessed by a

116 The predictive value of WRF on cardiovascular morbidity and mortality was examined duri

117 Cardiovascular morbidity and mortality were hypothesized

118 has contributed to a significant decrease in cardiovascular morbidity and mortality, although the ben

119 ructive sleep apnea (OSA) is associated with cardiovascular morbidity and mortality, although the und

120 Reduced kidney function is a risk factor for cardiovascular morbidity and mortality, and both heart f

121 failure is one of the most common causes of cardiovascular morbidity and mortality, and hypertension

122 common in women, is associated with adverse cardiovascular morbidity and mortality, and is a major b

123 left ventricular hypertrophy (LVH) predicts cardiovascular morbidity and mortality, and regression o

124 are not only epidemiologically connected to cardiovascular morbidity and mortality, but can also be

125 e work environment have been associated with cardiovascular morbidity and mortality, but it is unclea

126 iation of depression and phobic anxiety with cardiovascular morbidity and mortality, but little is kn

127 lution has been consistently associated with cardiovascular morbidity and mortality, but mechanisms r

128 dothelial dysfunction and increased risk for cardiovascular morbidity and mortality, but the state of

129 Treating depression may have an impact on cardiovascular morbidity and mortality, but this has not

130 this guideline included all-cause mortality, cardiovascular morbidity and mortality, cerebrovascular

131 on has emerged as a significant predictor of cardiovascular morbidity and mortality, challenging prev

132 idelines-recommended therapies have impacted cardiovascular morbidity and mortality, endovascular int

133 ular calcification is highly associated with cardiovascular morbidity and mortality, especially in pa

134 ciated with 2.4- to 3.4-fold higher risks of cardiovascular morbidity and mortality, independent of e

135 Elevated levels of NT-proBNP predict cardiovascular morbidity and mortality, independent of o

136 iffness has independent prognostic value for cardiovascular morbidity and mortality, its predictors m

137 Unlike cardiovascular morbidity and mortality, little is known

138 ch has already been demonstrated to decrease cardiovascular morbidity and mortality, provides signifi

139 ough depression is associated with increased cardiovascular morbidity and mortality, there is virtual

140 The primary outcome, cardiovascular morbidity and mortality, was analysed by

141 abetes mellitus is associated with increased cardiovascular morbidity and mortality, which in part ma

142 Diabetic patients are a high-risk group for cardiovascular morbidity and mortality, with poorer long

143 rlipidemia, is a significant risk factor for cardiovascular morbidity and mortality.

144 PAD is associated with increased risk of cardiovascular morbidity and mortality.

145 ions between ambient O(3) concentrations and cardiovascular morbidity and mortality.

146 stic information regarding long-term risk of cardiovascular morbidity and mortality.

147 ention and is associated with postprocedural cardiovascular morbidity and mortality.

148 tant hypertension that might result in lower cardiovascular morbidity and mortality.

149 ion may collectively contribute to increased cardiovascular morbidity and mortality.

150 structure and function were associated with cardiovascular morbidity and mortality.

151 azepril plus hydrochlorothiazide in reducing cardiovascular morbidity and mortality.

152 which is associated with markedly increased cardiovascular morbidity and mortality.

153 and is associated with significant limb and cardiovascular morbidity and mortality.

154 age, is associated with an increased risk of cardiovascular morbidity and mortality.

155 as a mechanism by which active RA increases cardiovascular morbidity and mortality.

156 tion between preventive measures and reduced cardiovascular morbidity and mortality.

157 r extremity performance, and higher rates of cardiovascular morbidity and mortality.

158 lar calcification is a major risk factor for cardiovascular morbidity and mortality.

159 reatment of sleep apnea in the prevention of cardiovascular morbidity and mortality.

160 ance, and hypertension, is a risk factor for cardiovascular morbidity and mortality.

161 king on large longitudinal studies to assess cardiovascular morbidity and mortality.

162 Atherosclerosis remains the leading cause of cardiovascular morbidity and mortality.

163 syndromes and is associated with substantial cardiovascular morbidity and mortality.

164 ir pollutants are positively associated with cardiovascular morbidity and mortality.

165 adverse health effects, including increased cardiovascular morbidity and mortality.

166 Diabetes mellitus is a major risk factor for cardiovascular morbidity and mortality.

167 s been shown to be associated with increased cardiovascular morbidity and mortality.

168 ted by heart failure is associated with high cardiovascular morbidity and mortality.

169 nd incident ECG abnormalities with long-term cardiovascular morbidity and mortality.

170 n and canagliflozin have been shown to lower cardiovascular morbidity and mortality.

171 nic kidney disease are at increased risk for cardiovascular morbidity and mortality.

172 ietary fiber appears to decrease the risk of cardiovascular morbidity and mortality.

173 latelet activation have successfully reduced cardiovascular morbidity and mortality.

174 ally to improve quality of life and decrease cardiovascular morbidity and mortality.

175 y the association of serum urate levels with cardiovascular morbidity and mortality.

176 sion remains the most common risk factor for cardiovascular morbidity and mortality.

177 ifestyle-related risk factors (LRFs) reduces cardiovascular morbidity and mortality.

178 end-stage renal disease are at high risk for cardiovascular morbidity and mortality.

179 Vascular calcification is associated with cardiovascular morbidity and mortality.

180 (LDL) particles are a major risk factor for cardiovascular morbidity and mortality.

181 n the exercise volume and risk reductions in cardiovascular morbidity and mortality.

182 perience an acute MI might reduce subsequent cardiovascular morbidity and mortality.

183 Statins reduce serum cholesterol and cardiovascular morbidity and mortality.

184 d cardiomyopathy is now the leading cause of cardiovascular morbidity and mortality.

185 n this area as a major influence in reducing cardiovascular morbidity and mortality.

186 al disease (ESRD), and it has been linked to cardiovascular morbidity and mortality.

187 ugs reduce both atherogenic lipoproteins and cardiovascular morbidity and mortality.

188 iovascular stiffness as well as the risk for cardiovascular morbidity and mortality.

189 hazard, and it contributes significantly to cardiovascular morbidity and mortality.

190 mplementary management strategy for reducing cardiovascular morbidity and mortality.

191 Left ventricular mass is a risk factor for cardiovascular morbidity and mortality.

192 -stage renal disease is associated with high cardiovascular morbidity and mortality.

193 ophy is associated with an increased risk of cardiovascular morbidity and mortality.

194 ures is associated with a marked increase in cardiovascular morbidity and mortality.

195 nts has been explored as a means of reducing cardiovascular morbidity and mortality.

196 ubgroups in the relation of sodium intake to cardiovascular morbidity and mortality.

197 Total mortality and cardiovascular morbidity and mortality.

198 and control measures to decrease associated cardiovascular morbidity and mortality.

199 and is associated with an increased risk of cardiovascular morbidity and mortality.

200 heart rate is significantly associated with cardiovascular morbidity and mortality.

201 ion between the level of serum uric acid and cardiovascular morbidity and mortality.

202 ly patients and is an important predictor of cardiovascular morbidity and mortality.

203 n either lowering blood pressure or reducing cardiovascular morbidity and mortality.

204 umption is associated with a reduced risk of cardiovascular morbidity and mortality.

205 process that is associated with significant cardiovascular morbidity and mortality.

206 obstruction after infarction predicts 2-year cardiovascular morbidity and mortality.

207 Obesity is associated with increased cardiovascular morbidity and mortality.

208 ary sodium in the US population could reduce cardiovascular morbidity and mortality.

209 l lowering is associated with a reduction in cardiovascular morbidity and mortality.

210 ertension is intended to prevent: stroke and cardiovascular morbidity and mortality.

211 OSA leads to high cardiovascular morbidity and mortality.

212 tients with diabetes mellitus to reduce both cardiovascular morbidity and mortality.

213 therosclerosis that is manifest by increased cardiovascular morbidity and mortality.

214 ness (CRF) is an independent risk factor for cardiovascular morbidity and mortality.

215 Hypertension contributes to cardiovascular morbidity and mortality.

216 ral artery disease have an increased risk of cardiovascular morbidity and mortality.

217 rotic disease, and association with incident cardiovascular morbidity and mortality.

218 e, and it is a strong predictor of increased cardiovascular morbidity and mortality.

219 atherosclerosis, which may lead to increased cardiovascular morbidity and mortality.

220 It is also linked with worse cardiovascular morbidity and mortality.

221 nts with HFpEF at particularly high risk for cardiovascular morbidity and mortality.

222 ntify patients at particularly high risk for cardiovascular morbidity and mortality.

223 idemiological findings of increased risk for cardiovascular morbidity and mortality.

224 iabetes mellitus are a major risk factor for cardiovascular morbidity and mortality.

225 anagement of dyslipidemia can markedly alter cardiovascular morbidity and mortality.

226 2.5 microm (PM2.5) has been associated with cardiovascular morbidity and mortality.

227 alternative regimens in an effort to reduce cardiovascular morbidity and mortality.

228 ween air pollution exposure and increases in cardiovascular morbidity and mortality.

229 ction patients at particularly high risk for cardiovascular morbidity and mortality.

230 t failure often coexist, causing substantial cardiovascular morbidity and mortality.

231 GH were associated with an increased risk of cardiovascular morbidity and mortality.

232 lution and temperature have been linked with cardiovascular morbidity and mortality.

233 The primary outcome was a composite of cardiovascular morbidity and mortality.

234 sity lipoprotein cholesterol (LDL-C) reduces cardiovascular morbidity and mortality.

235 sult in clinically significant reductions in cardiovascular morbidity and mortality.

236 as been associated with an increased risk of cardiovascular morbidity and mortality; however, the ind

237 s is associated with increased prevalence of cardiovascular morbidity and mortality; however, the nat

238 calcium burden is a significant predictor of cardiovascular morbidity and mortality; however, the und

239 hostility has been associated with increased cardiovascular morbidity and mortality; yet few studies

240 Obstructive sleep apnea causes cardiovascular morbidity and premature death.

241 Although aspirin has been shown to reduce cardiovascular morbidity and short-term mortality follow

242 albuminuria are also predictive of diabetes, cardiovascular morbidity, and death in nontransplanted p

243 hypertension, osteoporosis, central obesity, cardiovascular morbidity, and increased mortality.

244 recognized as playing a significant role in cardiovascular morbidity, and its role in hypertension h

245 lureas; the evidence on all-cause mortality, cardiovascular morbidity, and microvascular complication

246 t for the end points of all-cause mortality, cardiovascular morbidity, and mortality.

247 ublic awareness and education may reduce the cardiovascular morbidity associated with cocaine use.

248 nonwhite race, lower income, older age, less cardiovascular morbidity at initiation of therapy, depre

249 ars and postponed the onset of all-cause and cardiovascular morbidity by 4.5 and 7 years, respectivel

250 critical limb ischemia have a perioperative cardiovascular morbidity comparable to patients with acu

251 erview of the association between stress and cardiovascular morbidity, discuss the mechanisms for thi

252 This study compared mortality and cardiovascular morbidity during percutaneous coronary in

253 s the third leading cause of atherosclerotic cardiovascular morbidity, following coronary artery dise

254 tion in endothelial health and the long-term cardiovascular morbidity for children with primary syste

255 Cardiovascular morbidity has been associated with partic

256 1.16) or multivariable adjustment, including cardiovascular morbidities (hazard ratio, 0.94; 95% conf

257 ), was found to be associated with increased cardiovascular morbidity; however, another such drug, ce

258 fruit and vegetable consumption with reduced cardiovascular morbidity; however, there is little direc

259 des and contribute to thrombus formation and cardiovascular morbidities in HIV infection.

260 Their association with cardiovascular morbidity in addition to their suboptimal

261 evelops in childhood to decrease the risk of cardiovascular morbidity in adulthood.

262 are probably involved in the pathogenesis of cardiovascular morbidity in CCSs.

263 sma levels of TMAO, which is associated with cardiovascular morbidity in chronic kidney disease (CKD)

264 ion is identified as a major risk factor for cardiovascular morbidity in most larger population-based

265 lar risk factors and could potentially lower cardiovascular morbidity in NIDDM patients.

266 The magnitude of cardiovascular morbidity in paediatric, adolescent, and

267 The true effect of cardiovascular morbidity in paediatric, adolescent, and

268 Higher cardiovascular morbidity in patients with a wide range o

269 mass (LVM) is associated with mortality and cardiovascular morbidity in patients with end-stage rena

270 th that of a placebo on overall survival and cardiovascular morbidity in patients with or at risk for

271 ions in T cell lymphocytes may contribute to cardiovascular morbidity in pediatric OSA.

272 Statins reduce atherosclerosis and cardiovascular morbidity in the general population, but

273 risk factor for hypertension and consequent cardiovascular morbidity in the general population.

274 ese and diabetic patients and contributes to cardiovascular morbidity in these disorders.

275 cesses associated with OSA may contribute to cardiovascular morbidity in these patients.

276 iatric surgery improves predictors of future cardiovascular morbidity in these young people.

277 sm (PA) is common and associates with excess cardiovascular morbidity independent of blood pressure.

278 The rate of fetal loss and maternal cardiovascular morbidity is increased.

279 idney transplant recipients, predicts future cardiovascular morbidity is unclear.

280 ot specifically powered to detect changes in cardiovascular morbidity, length of stay, or mortality.

281 similar cardiovascular mortality (P=0.246), cardiovascular morbidity/mortality (P=0.783), and reason

282 ammatory condition associated with increased cardiovascular morbidity/mortality and an incompletely u

283 ammatory condition associated with increased cardiovascular morbidity/mortality and an incompletely u

284 use mortality, cardiovascular mortality, and cardiovascular morbidity/mortality were analyzed by use

285 were mortality (n=96, 19+/-2% at 10 years), cardiovascular morbidity (n=171), and MVP-related events

286 sleep complaints, short sleep duration, and cardiovascular morbidity observed in epidemiologic surve

287 ortality of 5+/-2% (P=0.17 versus expected), cardiovascular morbidity of 0.5%/y, and MVP-related even

288 These risk factors are often associated with cardiovascular morbidity or mortality and with total mor

289 There was no increased risk of cardiovascular morbidity or mortality associated with va

290 tazone does not increase the risk of overall cardiovascular morbidity or mortality compared with stan

291 hysiologic outcomes, diabetes incidence, and cardiovascular morbidity or mortality in adults with CVD

292 Amlodipine did not increase cardiovascular morbidity or mortality in patients with s

293 obesity medication has been shown to reduce cardiovascular morbidity or mortality.

294 n individual's all-cause morbidity score and cardiovascular morbidity score were calculated from Inte

295 p apnea (OSA) in children is associated with cardiovascular morbidity such as systemic and pulmonary

296 Information on all-cause mortality and cardiovascular morbidity (such as the acute coronary syn

297 IGT is more predictive of cardiovascular morbidity than impaired fasting glucose,

298 Freedom from any cardiovascular morbidity was 88% at 15 years and 84% at

299 Cardiovascular morbidity was defined as new episodes of

300 ary risk factors independently predictive of cardiovascular morbidity were slight mitral regurgitatio